Back to News
Market Impact: 0.15
Oncolytics Biotech Inc. Reports Updated Clinical Data from Cohort 4 of GOBLET Study
Source: Nasdaq
Healthcare & Biotech
Oncolytics Biotech announced updated clinical data from Cohort 4 of its Phase 1/2 GOBLET study, evaluating pelareorep with atezolizumab in patients with second-line or later squamous cell anal cancer. The provided article text ends before reporting the data; it notes only that median overall survival has not yet been [reported/completed].
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- adar1 capital management buys $53,691 of NextCure stock
- Zura Bio shares jump on Wedbush buy call ahead of trial data
- Why is Artiva Biotherapeutics stock collapsing today?